Viewing Study NCT04566367


Ignite Creation Date: 2025-12-25 @ 12:36 AM
Ignite Modification Date: 2026-01-01 @ 6:06 PM
Study NCT ID: NCT04566367
Status: UNKNOWN
Last Update Posted: 2023-07-13
First Post: 2018-12-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
Sponsor: Georg Dultz
Organization:

Study Overview

Official Title: Detection Rate by Blue Laser Imaging (BLI) of Secondary or Early Squamous Head and Neck Cancer in Patients Undergoing Elective Percutaneous Endoscopic Gastrostomy (PEG)
Status: UNKNOWN
Status Verified Date: 2023-06
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study wants to focus on Carcinoma detection rates with blue laser imaging (BLI) for participants with head-neck cancer who need a percutaneous endoscopic gastrostomy (PEG). BLI is a new imaging technique that can easily be used within a standard gastroscopy.
Detailed Description: Head-Neck cancers are a significant burden all around the world. Patients suffering from one tumor are at high risk for a second cancer or another precancerous lesion. Before or during cancer treatment a PEG is needed to maintain a sufficient calories intake. PEG is established by performing a standard gastroscopy.

This randomised study wants to compare the detection rates of standard white light endoscopy compared to the additional use of blue laser imaging for second cancers or precancerous lesions in participants presenting for PEG establishment.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: